{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T15:47:01Z","timestamp":1791215221080,"version":"4.1.0"},"reference-count":133,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2015,7,1]],"date-time":"2015-07-01T00:00:00Z","timestamp":1435708800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Pharmaceutical Sciences"],"published-print":{"date-parts":[[2015,7]]},"DOI":"10.1016\/j.ejps.2015.04.011","type":"journal-article","created":{"date-parts":[[2015,5,2]],"date-time":"2015-05-02T20:48:16Z","timestamp":1430599696000},"page":"40-53","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":19,"special_numbering":"C","title":["Improving bioavailability and biodistribution of anti-HIV chemotherapy"],"prefix":"10.1016","volume":"75","author":[{"given":"Giovanna","family":"Giacalone","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Herv\u00e9","family":"Hillaireau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elias","family":"Fattal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"12","key":"10.1016\/j.ejps.2015.04.011_b0005","doi-asserted-by":"crossref","first-page":"1630","DOI":"10.1002\/adhm.201200454","article-title":"Towards an improved anti-HIV activity of NRTI via metal-organic frameworks nanoparticles","volume":"2","author":"Agostoni","year":"2013","journal-title":"Adv. Healthcare Mater."},{"issue":"1","key":"10.1016\/j.ejps.2015.04.011_b0010","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/S0378-5173(97)04887-4","article-title":"Antisense oligonucleotide delivery to cultured macrophages is improved by incorporation into sustained-release biodegradable polymer microspheres","volume":"151","author":"Akhtar","year":"1997","journal-title":"Int. J. Pharm."},{"issue":"1\u20132","key":"10.1016\/j.ejps.2015.04.011_b0015","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/j.ijpharm.2008.01.029","article-title":"Development of an implantable infusion pump for sustained anti-HIV drug administration","volume":"355","author":"Baert","year":"2008","journal-title":"Int. J. Pharm."},{"issue":"11","key":"10.1016\/j.ejps.2015.04.011_b0020","doi-asserted-by":"crossref","first-page":"6127","DOI":"10.1016\/S0021-9258(18)83322-1","article-title":"Differential patterns of intracellular metabolism of 2\u2032,3\u2032-didehydro-2\u2032,3\u2032-dideoxythymidine and 3\u2032-azido-2\u2032,3\u2032-dideoxythymidine, 2 potent anti-human immunodeficiency virus compounds","volume":"264","author":"Balzarini","year":"1989","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.ejps.2015.04.011_b0025","first-page":"6049","article-title":"Colloidal gold-loaded, biodegradable, polymer-based stavudine nanoparticle uptake by macrophages: an in vitro study","volume":"7","author":"Basu","year":"2012","journal-title":"Int. J. Nanomed."},{"issue":"6","key":"10.1016\/j.ejps.2015.04.011_b0030","doi-asserted-by":"crossref","first-page":"1467","DOI":"10.1128\/AAC.40.6.1467","article-title":"Efficiency of nanoparticles as a carrier system for antiviral agents in human immunodeficiency virus-infected human monocytes\/macrophages in vitro","volume":"40","author":"Bender","year":"1996","journal-title":"Antimicrob. Agents Chemother."},{"issue":"16","key":"10.1016\/j.ejps.2015.04.011_b0035","doi-asserted-by":"crossref","first-page":"2109","DOI":"10.3109\/03639049309069345","article-title":"Drug-delivery using antibody-liposome conjugates","volume":"19","author":"Betageri","year":"1993","journal-title":"Drug Dev. Ind. Pharm."},{"key":"10.1016\/j.ejps.2015.04.011_b0040","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1146\/annurev.med.53.082901.104024","article-title":"The challenge of viral reservoirs in HIV-1 infection","volume":"53","author":"Blankson","year":"2002","journal-title":"Annu. Rev. Med."},{"issue":"2A","key":"10.1016\/j.ejps.2015.04.011_b0045","first-page":"189","article-title":"Pharmacokinetics and bioavailability of zidovudine in humans","volume":"85","author":"Blum","year":"1988","journal-title":"Am. J. Med."},{"issue":"3","key":"10.1016\/j.ejps.2015.04.011_b0050","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/S0928-0987(02)00080-5","article-title":"Synthesis and in vitro chemical and enzymatic stability of glycosyl 3\u2032-azido-3\u2032-deoxythymidine derivatives as potential anti-HIV agents","volume":"16","author":"Bonina","year":"2002","journal-title":"Eur. J. Pharm. Sci."},{"issue":"8","key":"10.1016\/j.ejps.2015.04.011_b0055","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1089\/aid.2010.0295","article-title":"Efficacy of tat-conjugated ritonavir-loaded nanoparticles in reducing HIV-1 replication in monocyte-derived macrophages and cytocompatibility with macrophages and human neurons","volume":"27","author":"Borgmann","year":"2011","journal-title":"Aids Res. Hum. Retrovir."},{"issue":"14","key":"10.1016\/j.ejps.2015.04.011_b0060","doi-asserted-by":"crossref","first-page":"7887","DOI":"10.1074\/jbc.271.14.7887","article-title":"Cellular phosphorylation of Anti-HIV nucleosides \u2013 role of nucleoside diphosphate kinase","volume":"271","author":"Bourdais","year":"1996","journal-title":"J. Biol. Chem."},{"issue":"8","key":"10.1016\/j.ejps.2015.04.011_b0065","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.1023\/A:1010931127745","article-title":"Long-circulating PEGylated polycyanoacrylate nanoparticles as new drug carrier for brain delivery","volume":"18","author":"Calvo","year":"2001","journal-title":"Pharm. Res."},{"issue":"1","key":"10.1016\/j.ejps.2015.04.011_b0070","doi-asserted-by":"crossref","first-page":"11","DOI":"10.2217\/nnm.09.90","article-title":"Efavirenz-loaded polymeric micelles for pediatric anti-HIV pharmacotherapy with significantly higher oral bioavailaibility","volume":"5","author":"Chiappetta","year":"2010","journal-title":"Nanomedicine"},{"issue":"2","key":"10.1016\/j.ejps.2015.04.011_b0075","doi-asserted-by":"crossref","first-page":"223","DOI":"10.2217\/nnm.12.104","article-title":"Intranasal administration of antiretroviral-loaded micelles for anatomical targeting to the brain in HIV","volume":"8","author":"Chiappetta","year":"2013","journal-title":"Nanomedicine"},{"key":"10.1016\/j.ejps.2015.04.011_b0080","doi-asserted-by":"crossref","DOI":"10.1186\/1742-4690-6-51","article-title":"HIV interactions with monocytes and dendritic cells: viral latency and reservoirs","volume":"6","author":"Coleman","year":"2009","journal-title":"Retrovirology"},{"issue":"3","key":"10.1016\/j.ejps.2015.04.011_b0085","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1097\/COH.0b013e32835fc68a","article-title":"Overcoming pharmacologic sanctuaries","volume":"8","author":"Cory","year":"2013","journal-title":"Curr. Opin. HIV AIDS"},{"issue":"12","key":"10.1016\/j.ejps.2015.04.011_b0090","doi-asserted-by":"crossref","first-page":"1669","DOI":"10.2165\/00003495-200565120-00005","article-title":"Tipranavir \u2013 a ritonavir-boosted protease inhibitor","volume":"65","author":"Croom","year":"2005","journal-title":"Drugs"},{"issue":"2","key":"10.1016\/j.ejps.2015.04.011_b0095","first-page":"129","article-title":"Macrophages and residual HIV infection","volume":"1","author":"Crowe","year":"2006","journal-title":"Curr. Opin. HIV AIDS"},{"issue":"6","key":"10.1016\/j.ejps.2015.04.011_b0100","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1016\/0166-3542(90)90053-A","article-title":"Synthesis and anti-HIV evaluation of some phosphoramidate derivatives of Azt \u2013 studies on the effect of chain elongation on biological-activity","volume":"14","author":"Curley","year":"1990","journal-title":"Antiviral Res."},{"issue":"4\u20135","key":"10.1016\/j.ejps.2015.04.011_b0105","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1016\/j.addr.2009.11.017","article-title":"Nanotechnology-based systems for the treatment and prevention of HIV\/AIDS","volume":"62","author":"Neves","year":"2010","journal-title":"Adv. Drug Deliv. Rev."},{"issue":"8","key":"10.1016\/j.ejps.2015.04.011_b0110","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1038\/nri3262","article-title":"The International AIDS Society Scientific Working Group on HIV Cure, towards an HIV cure: a global scientific strategy","volume":"12","author":"Deeks","year":"2012","journal-title":"Nat. Rev. Immunol."},{"issue":"4","key":"10.1016\/j.ejps.2015.04.011_b0115","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1023\/A:1011050209986","article-title":"Targeting of 3\u2032-azido 3\u2032-deoxythymidine (AZT)-loaded poly(isohexylcyanoacrylate) nanospheres to the gastrointestinal mucosa and associated lymphoid tissues","volume":"18","author":"Dembri","year":"2001","journal-title":"Pharm. Res."},{"issue":"11","key":"10.1016\/j.ejps.2015.04.011_b0120","doi-asserted-by":"crossref","first-page":"1545","DOI":"10.1097\/00002030-199411000-00005","article-title":"Antiviral efficacy, intracellular uptake and pharmacokinetics of free and liposome-encapsulated 2\u2032,3\u2032-dideoxyinosine","volume":"8","author":"Desormeaux","year":"1994","journal-title":"Aids"},{"issue":"10","key":"10.1016\/j.ejps.2015.04.011_b0125","doi-asserted-by":"crossref","first-page":"2183","DOI":"10.1093\/jac\/dkq318","article-title":"Antiretroviral release from poly(dl-lactide-co-glycolide) nanoparticles in mice","volume":"65","author":"Destache","year":"2010","journal-title":"J. Antimicrob. Chemother."},{"issue":"3","key":"10.1016\/j.ejps.2015.04.011_b0130","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1016\/j.jconrel.2004.02.020","article-title":"Intracellular tracking of protamine\/antisense oligonucleotide nanoparticles and their inhibitory effect on HIV-1 transactivation","volume":"96","author":"Dinauer","year":"2004","journal-title":"J. Control. Release"},{"issue":"2","key":"10.1016\/j.ejps.2015.04.011_b0135","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1208\/s12248-012-9329-6","article-title":"Design and characterization of novel peptide-coated lipid nanoparticles for targeting anti-HIV drug to CD4 expressing cells","volume":"14","author":"Endsley","year":"2012","journal-title":"AAPS J."},{"key":"10.1016\/j.ejps.2015.04.011_b0140","unstructured":"European AIDS Clinical Society, 2011. Guidelines Version 7.0. <www.eacsociety.org\/Portals\/0\/Guidelines_Online_131014.pdf>."},{"issue":"3","key":"10.1016\/j.ejps.2015.04.011_b0145","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1016\/S0166-3542(00)00101-7","article-title":"A new acyclic heterodinucleotide active against human immunodeficiency virus and herpes simplex virus","volume":"47","author":"Franchetti","year":"2000","journal-title":"Antiviral Res."},{"issue":"5","key":"10.1016\/j.ejps.2015.04.011_b0150","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1007\/s11051-008-9357-4","article-title":"Drug nanocrystals for the formulation of poorly soluble drugs and its application as a potential drug delivery system","volume":"10","author":"Gao","year":"2008","journal-title":"J. Nanopart. Res."},{"issue":"1","key":"10.1016\/j.ejps.2015.04.011_b0155","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1080\/10611860500525370","article-title":"Reduced hematopoietic toxicity, enhanced cellular uptake and altered pharmacokinetics of azidothymidine loaded galactosylated liposomes","volume":"14","author":"Garg","year":"2006","journal-title":"J. Drug Target."},{"issue":"2","key":"10.1016\/j.ejps.2015.04.011_b0160","first-page":"64","article-title":"Hydrosols \u2013 alternatives for the parenteral application of poorly water-soluble drugs","volume":"40","author":"Gassmann","year":"1994","journal-title":"Eur. J. Pharm. Biopharm."},{"issue":"5","key":"10.1016\/j.ejps.2015.04.011_b0165","doi-asserted-by":"crossref","first-page":"759","DOI":"10.3851\/IMP1803","article-title":"Efficacy and safety of nevirapine extended-release once daily versus nevirapine immediate-release twice-daily in treatment-naive HIV-1-infected patients","volume":"16","author":"Gathe","year":"2011","journal-title":"Antiviral Therapy"},{"issue":"7","key":"10.1016\/j.ejps.2015.04.011_b0170","doi-asserted-by":"crossref","first-page":"3110","DOI":"10.1128\/AAC.00267-13","article-title":"Preclinical pharmacokinetics and tissue distribution of long-acting nanoformulated antiretroviral therapy","volume":"57","author":"Gautam","year":"2013","journal-title":"Antimicrob. Agents Chemother."},{"issue":"3","key":"10.1016\/j.ejps.2015.04.011_b0175","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1021\/bm301832v","article-title":"Drug-induced nanocarrier assembly as a strategy for the cellular delivery of nucleotides and nucleotide analogues","volume":"14","author":"Giacalone","year":"2013","journal-title":"Biomacromolecules"},{"issue":"5","key":"10.1016\/j.ejps.2015.04.011_b0180","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1111\/j.0300-9475.2004.01431.x","article-title":"DC-SIGN-specific liposomal targeting and selective intracellular compound delivery to human myeloid dendritic cells: implications for HIV disease","volume":"59","author":"Gieseler","year":"2004","journal-title":"Scand. J. Immunol."},{"issue":"4-5","key":"10.1016\/j.ejps.2015.04.011_b0185","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1016\/j.addr.2009.11.018","article-title":"Non-polymeric nano-carriers in HIV\/AIDS drug delivery and targeting","volume":"62","author":"Gupta","year":"2010","journal-title":"Adv. Drug Deliv. Rev."},{"issue":"8","key":"10.1016\/j.ejps.2015.04.011_b0190","doi-asserted-by":"crossref","first-page":"1154","DOI":"10.1023\/A:1011919319810","article-title":"5\u2032-amino acid esters of antiviral nucleosides, acyclovir, and AZT are absorbed by the intestinal PEPT1 peptide transporter","volume":"15","author":"Han","year":"1998","journal-title":"Pharm. Res."},{"issue":"3","key":"10.1016\/j.ejps.2015.04.011_b0195","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1016\/j.jconrel.2006.09.016","article-title":"Hybrid polymer nanocapsules enhance in vitro delivery of azidothymidine-triphosphate to macrophages","volume":"116","author":"Hillaireau","year":"2006","journal-title":"J. Control. Release"},{"issue":"1","key":"10.1016\/j.ejps.2015.04.011_b0200","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/j.ijpharm.2006.07.006","article-title":"Encapsulation of antiviral nucleotide analogues azidothymidine-triphosphate and cidofovir in poly(iso-butylcyanoacrylate) nanocapsules","volume":"324","author":"Hillaireau","year":"2006","journal-title":"Int. J. Pharm."},{"issue":"2","key":"10.1016\/j.ejps.2015.04.011_b0205","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1016\/j.ijpharm.2006.10.031","article-title":"Encapsulation of mono- and oligo-nucleotides into aqueous-core nanocapsules in presence of various water-soluble polymers","volume":"331","author":"Hillaireau","year":"2007","journal-title":"Int. J. Pharm."},{"issue":"20","key":"10.1016\/j.ejps.2015.04.011_b0210","doi-asserted-by":"crossref","first-page":"4831","DOI":"10.1016\/j.biomaterials.2013.03.022","article-title":"Anti-HIV efficacy and biodistribution of nucleoside reverse transcriptase inhibitors delivered as squalenoylated prodrug nanoassemblies","volume":"34","author":"Hillaireau","year":"2013","journal-title":"Biomaterials"},{"issue":"3","key":"10.1016\/j.ejps.2015.04.011_b0215","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1016\/S0168-3659(00)00319-9","article-title":"Enhanced delivery of AZT to macrophages via acetylated LDL","volume":"69","author":"Hu","year":"2000","journal-title":"J. Control. Release"},{"issue":"1\u20132","key":"10.1016\/j.ejps.2015.04.011_b0220","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1016\/j.ijpharm.2009.11.018","article-title":"Self-assembled drug delivery systems. Part 5: Self-assemblies of a bolaamphiphilic prodrug containing dual zidovudine","volume":"386","author":"Jin","year":"2010","journal-title":"Int. J. Pharm."},{"issue":"3","key":"10.1016\/j.ejps.2015.04.011_b0225","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1021\/mp100457d","article-title":"Combination anti-HIV therapy with the self-assemblies of an asymmetric bolaamphiphilic zidovudine\/didanosine prodrug","volume":"8","author":"Jin","year":"2011","journal-title":"Mol. Pharm."},{"issue":"6","key":"10.1016\/j.ejps.2015.04.011_b0230","doi-asserted-by":"crossref","first-page":"975","DOI":"10.2217\/nnm.11.27","article-title":"Macrophage endocytic trafficking of antiretroviral nanoparticles","volume":"6","author":"Kadiu","year":"2011","journal-title":"Nanomedicine"},{"key":"10.1016\/j.ejps.2015.04.011_b0235","doi-asserted-by":"crossref","DOI":"10.1155\/2014\/959741","article-title":"Formulation and characterization of drug loaded nonionic surfactant vesicles (niosomes) for oral bioavailability enhancement","author":"Kamboj","year":"2014","journal-title":"Sci. World J."},{"key":"10.1016\/j.ejps.2015.04.011_b0240","doi-asserted-by":"crossref","first-page":"2373","DOI":"10.2147\/IJN.S29454","article-title":"Mononuclear phagocyte intercellular crosstalk facilitates transmission of cell-targeted nanoformulated antiretroviral drugs to human brain endothelial cells","volume":"7","author":"Kanmogne","year":"2012","journal-title":"Int. J. Nanomed."},{"issue":"1-2","key":"10.1016\/j.ejps.2015.04.011_b0245","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1016\/j.ijpharm.2012.01.005","article-title":"In situ forming implant for controlled delivery of an anti-HIV fusion inhibitor","volume":"426","author":"Kapoor","year":"2012","journal-title":"Int. J. Pharm."},{"issue":"6","key":"10.1016\/j.ejps.2015.04.011_b0250","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1002\/jps.2600790616","article-title":"Ester prodrugs of zidovudine","volume":"79","author":"Kawaguchi","year":"1990","journal-title":"J. Pharm. Sci."},{"issue":"1","key":"10.1016\/j.ejps.2015.04.011_b0255","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1016\/j.bmcl.2012.10.095","article-title":"Design and synthesis of HIV-1 protease inhibitors for a long-acting injectable drug application","volume":"23","author":"Kesteleyn","year":"2013","journal-title":"Bioorg. Med. Chem. Lett."},{"issue":"6","key":"10.1016\/j.ejps.2015.04.011_b0260","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1517\/17425251003713501","article-title":"Anti-HIV therapy with AZT prodrugs: AZT phosphonate derivatives, current state and prospects","volume":"6","author":"Khandazhinskaya","year":"2010","journal-title":"Expert Opin. Drug Metab. Toxicol."},{"issue":"2","key":"10.1016\/j.ejps.2015.04.011_b0265","first-page":"80","article-title":"Preparation and characterization of poly(lactide-co-glycolide) microspheres for the sustained release of AZT","volume":"8","author":"Khang","year":"2000","journal-title":"Korea Polym. J."},{"issue":"3","key":"10.1016\/j.ejps.2015.04.011_b0270","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1021\/bm060711a","article-title":"Translocation of poly(ethylene glycol-co-hexadecyl)cyanoacrylate nanoparticles into rat brain endothelial cells: role of apolipoproteins in receptor-mediated endocytosis","volume":"8","author":"Kim","year":"2007","journal-title":"Biomacromolecules"},{"issue":"3","key":"10.1016\/j.ejps.2015.04.011_b0275","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1007\/s00018-007-6390-x","article-title":"Low-density lipoprotein receptor-mediated endocytosis of PEGylated nanoparticles in rat brain endothelial cells","volume":"64","author":"Kim","year":"2007","journal-title":"Cell. Mol. Life Sci."},{"issue":"4","key":"10.1016\/j.ejps.2015.04.011_b0280","first-page":"387","article-title":"Lipid-drug association enhanced HIV-1 protease inhibitor indinavir localization in lymphoid tissues and viral load reduction: a proof of concept study in HIV-2(287)-infected macaques","volume":"34","author":"Kinman","year":"2003","journal-title":"Jaids"},{"issue":"1","key":"10.1016\/j.ejps.2015.04.011_b0285","first-page":"62","article-title":"State of the art in intravaginal ring technology for topical prophylaxis of HIV infection","volume":"14","author":"Kiser","year":"2012","journal-title":"Aids Rev."},{"issue":"9","key":"10.1016\/j.ejps.2015.04.011_b0290","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1002\/j.1552-4604.1988.tb03225.x","article-title":"Pharmacokinetics of 2\u2032,3\u2032-dideoxycytidine in patients with aids and related disorders","volume":"28","author":"Klecker","year":"1988","journal-title":"J. Clin. Pharmacol."},{"issue":"1-2","key":"10.1016\/j.ejps.2015.04.011_b0295","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/S0378-5173(00)00626-8","article-title":"Production and characterisation of highly concentrated nanosuspensions by high pressure homogenisation","volume":"214","author":"Krause","year":"2001","journal-title":"Int. J. Pharm."},{"issue":"5","key":"10.1016\/j.ejps.2015.04.011_b0300","doi-asserted-by":"crossref","first-page":"833","DOI":"10.3851\/IMP2076","article-title":"Pill burden in HIV infection: 20years of experience","volume":"17","author":"Krentz","year":"2012","journal-title":"Antiviral Therapy"},{"issue":"1","key":"10.1016\/j.ejps.2015.04.011_b0305","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/0006-8993(95)00023-J","article-title":"Passage of peptides through the blood-brain-barrier with colloidal polymer particles (nanoparticles)","volume":"674","author":"Kreuter","year":"1995","journal-title":"Brain Res."},{"issue":"1","key":"10.1016\/j.ejps.2015.04.011_b0310","doi-asserted-by":"crossref","DOI":"10.1208\/pt070101","article-title":"Formulation and in vitro, in vivo evaluation of extended-release matrix tablet of zidovudine: influence of combination of hydrophilic and hydrophobic matrix formers","volume":"7","author":"Kuksal","year":"2006","journal-title":"AAPS Pharmscitech."},{"issue":"10","key":"10.1016\/j.ejps.2015.04.011_b0315","doi-asserted-by":"crossref","first-page":"1767","DOI":"10.2174\/13816128113199990295","article-title":"Anti-HIV drug development: structural features and limitations of present day drugs and future challenges in the successful HIV\/AIDS treatment","volume":"19","author":"Kumari","year":"2013","journal-title":"Curr. Pharm. Des."},{"issue":"6","key":"10.1016\/j.ejps.2015.04.011_b0320","doi-asserted-by":"crossref","first-page":"884","DOI":"10.1023\/A:1016269206048","article-title":"Regiospecific intestinal-absorption of the HIV protease inhibitor L-735,524 in beagle dogs","volume":"12","author":"Kwei","year":"1995","journal-title":"Pharm. Res."},{"issue":"2","key":"10.1016\/j.ejps.2015.04.011_b0325","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1016\/j.ijpharm.2009.05.030","article-title":"Metabolism evaluation of biomimetic prodrugs by in vitro models and mass spectrometry","volume":"379","author":"Lalanne","year":"2009","journal-title":"Int. J. Pharm."},{"issue":"5","key":"10.1016\/j.ejps.2015.04.011_b0330","doi-asserted-by":"crossref","first-page":"846","DOI":"10.2165\/00003495-199651050-00009","article-title":"Stavudine \u2013 a review of its pharmacodynamic and pharmacokinetic properties and clinical potential in HIV infection","volume":"51","author":"Lea","year":"1996","journal-title":"Drugs"},{"issue":"12","key":"10.1016\/j.ejps.2015.04.011_b0335","doi-asserted-by":"crossref","first-page":"1517","DOI":"10.1038\/nbt1171","article-title":"Designing dendrimers for biological applications","volume":"23","author":"Lee","year":"2005","journal-title":"Nat. Biotechnol."},{"issue":"4","key":"10.1016\/j.ejps.2015.04.011_b0340","doi-asserted-by":"crossref","first-page":"291","DOI":"10.3109\/10611869808995882","article-title":"Development of a sustained-release biodegradable polymer delivery system for site-specific delivery of oligonucleotides: characterization of P(LA-GA) copolymer microspheres in vitro","volume":"5","author":"Lewis","year":"1998","journal-title":"J. Drug Target."},{"issue":"11","key":"10.1016\/j.ejps.2015.04.011_b0345","doi-asserted-by":"crossref","first-page":"1893","DOI":"10.1002\/cmdc.201000352","article-title":"Synthesis, in vitro and in vivo release kinetics, and anti-HIV activity of a sustained-release prodrug (mPEG-AZT) of 3\u2032-azido-3\u2032-deoxythymidine (AZT, Zidovudine)","volume":"5","author":"Li","year":"2010","journal-title":"ChemMedChem"},{"issue":"4","key":"10.1016\/j.ejps.2015.04.011_b0350","doi-asserted-by":"crossref","first-page":"974","DOI":"10.1016\/j.ijbiomac.2012.02.019","article-title":"Synthesis, drug release and anti-HIV activity of a series of PEGylated zidovudine conjugates","volume":"50","author":"Li","year":"2012","journal-title":"Int. J. Biol. Macromol."},{"key":"10.1016\/j.ejps.2015.04.011_b0355","unstructured":"Liversidge, G., Cundy, K.C., Bishop, J., et al., 1992. Surface modified drug nanoparticles. US Patent 5145684 1992, 8 Sept."},{"issue":"2","key":"10.1016\/j.ejps.2015.04.011_b0360","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/S0939-6411(97)00078-7","article-title":"Body distribution of azidothymidine bound to nanoparticles after oral administration","volume":"44","author":"Lobenberg","year":"1997","journal-title":"Eur. J. Pharm. Biopharm."},{"issue":"1\u20133","key":"10.1016\/j.ejps.2015.04.011_b0365","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/S0168-3659(97)00105-3","article-title":"Body distribution of azidothymidine bound to hexyl-cyanoacrylate nanoparticles after i.v. injection to rats","volume":"50","author":"Lobenberg","year":"1998","journal-title":"J. Control. Release"},{"issue":"14","key":"10.1016\/j.ejps.2015.04.011_b0370","doi-asserted-by":"crossref","first-page":"6477","DOI":"10.1073\/pnas.89.14.6477","article-title":"Targeting antiretroviral nucleoside analogs in phosphorylated form to macrophages \u2013 invitro and invivo studies","volume":"89","author":"Magnani","year":"1992","journal-title":"Proc. Natl. Acad. Sci. USA"},{"issue":"2","key":"10.1016\/j.ejps.2015.04.011_b0375","doi-asserted-by":"crossref","first-page":"148","DOI":"10.3109\/10717544.2013.838014","article-title":"Nanoemulsion-based intranasal drug delivery system of saquinavir mesylate for brain targeting","volume":"21","author":"Mahajan","year":"2014","journal-title":"Drug Deliv."},{"issue":"2","key":"10.1016\/j.ejps.2015.04.011_b0380","doi-asserted-by":"crossref","first-page":"269","DOI":"10.2217\/nnm.10.1","article-title":"Emerging nanotechnology approaches for HIV\/AIDS treatment and prevention","volume":"5","author":"Mamo","year":"2010","journal-title":"Nanomedicine (Lond.)"},{"issue":"3","key":"10.1016\/j.ejps.2015.04.011_b0385","doi-asserted-by":"crossref","first-page":"257","DOI":"10.3109\/02652049609026014","article-title":"Preparation of biodegradable microcapsules containing zidovudine (AZT) using solvent evaporation technique","volume":"13","author":"Mandal","year":"1996","journal-title":"J. Microencapsul."},{"issue":"8","key":"10.1016\/j.ejps.2015.04.011_b0390","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1517\/14656566.2013.782285","article-title":"Stavudine extended release (once-daily, Bristol-Myers Squibb) for the treatment of HIV\/AIDS","volume":"14","author":"Mateo","year":"2013","journal-title":"Expert Opin. Pharmacother."},{"issue":"3","key":"10.1016\/j.ejps.2015.04.011_b0395","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1016\/0166-3542(91)90071-X","article-title":"Synthesis and anti-HIV activity of some haloalkyl phosphoramidate derivatives of 3\u2032-azido-3\u2032-deoxythymidine (Azt) \u2013 potent activity of the trichloroethyl methoxyalaninyl compound","volume":"15","author":"Mcguigan","year":"1991","journal-title":"Antiviral Res."},{"issue":"2","key":"10.1016\/j.ejps.2015.04.011_b0400","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1097\/00002030-200101260-00007","article-title":"Reasons for modification and discontinuation of antiretrovirals: results from a single treatment centre","volume":"15","author":"Mocroft","year":"2001","journal-title":"Aids"},{"issue":"12","key":"10.1016\/j.ejps.2015.04.011_b0405","doi-asserted-by":"crossref","first-page":"2603","DOI":"10.1016\/0006-2952(90)90577-8","article-title":"Targeting of antiviral drugs to lymphocytes-T4 \u2013 anti-HIV activity of neoglycoprotein aztmp conjugates invitro","volume":"40","author":"Molema","year":"1990","journal-title":"Biochem. Pharmacol."},{"issue":"4","key":"10.1016\/j.ejps.2015.04.011_b0410","doi-asserted-by":"crossref","first-page":"2244","DOI":"10.1002\/app.31592","article-title":"Spray drying technique to produce controlled release formulations of zidovudine-an anti-HIV drug","volume":"122","author":"Mundargi","year":"2011","journal-title":"J. Appl. Polym. Sci."},{"issue":"7","key":"10.1016\/j.ejps.2015.04.011_b0415","doi-asserted-by":"crossref","first-page":"1568","DOI":"10.1128\/AAC.42.7.1568","article-title":"Antiretroviral efficacy and pharmacokinetics of oral bis(isopropyloxycarbonyloxymethyl) 9-(2-phosphonylmethoxypropyl)adenine in mice","volume":"42","author":"Naesens","year":"1998","journal-title":"Antimicrob. Agents Chemother."},{"issue":"6","key":"10.1016\/j.ejps.2015.04.011_b0420","doi-asserted-by":"crossref","first-page":"2976","DOI":"10.1021\/ja206867t","article-title":"Toward eradicating HIV reservoirs in the brain: inhibiting P-glycoprotein at the blood-brain barrier with prodrug abacavir dimers","volume":"134","author":"Namanja","year":"2012","journal-title":"J. Am. Chem. Soc."},{"issue":"4","key":"10.1016\/j.ejps.2015.04.011_b0425","doi-asserted-by":"crossref","first-page":"272","DOI":"10.3109\/10717544.2010.536272","article-title":"Poly(HEMA-Zidovudine) conjugate: a macromolecular pro-drug for improvement in the biopharmaceutical properties of the drug","volume":"18","author":"Neeraj","year":"2011","journal-title":"Drug Deliv."},{"issue":"6","key":"10.1016\/j.ejps.2015.04.011_b0430","doi-asserted-by":"crossref","first-page":"2913","DOI":"10.1128\/JVI.02356-09","article-title":"Viral sanctuaries during highly active antiretroviral therapy in a nonhuman primate model for AIDS","volume":"84","author":"North","year":"2010","journal-title":"J. Virol."},{"issue":"4","key":"10.1016\/j.ejps.2015.04.011_b0435","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1007\/s11481-010-9198-7","article-title":"Nanoformulated antiretroviral drug combinations extend drug release and antiretroviral responses in HIV-1-infected macrophages: implications for NeuroAIDS therapeutics","volume":"5","author":"Nowacek","year":"2010","journal-title":"J. Neuroimmune Pharm."},{"issue":"2","key":"10.1016\/j.ejps.2015.04.011_b0440","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1016\/j.jconrel.2010.11.019","article-title":"Analyses of nanoformulated antiretroviral drug charge, size, shape and content for uptake, drug release and antiviral activities in human monocyte-derived macrophages","volume":"150","author":"Nowacek","year":"2011","journal-title":"J. Control. Release"},{"issue":"3","key":"10.1016\/j.ejps.2015.04.011_b0445","first-page":"275","article-title":"Nanotechnology and drug delivery part 2: nanostructures for drug delivery","volume":"8","author":"Ochekpe","year":"2009","journal-title":"Trop. J. Pharm. Res."},{"issue":"3","key":"10.1016\/j.ejps.2015.04.011_b0450","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1016\/j.ejpb.2008.06.020","article-title":"Exploring the use of novel drug delivery systems for antiretroviral drugs","volume":"70","author":"Ojewole","year":"2008","journal-title":"Eur. J. Pharm. Biopharm."},{"issue":"2","key":"10.1016\/j.ejps.2015.04.011_b0455","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1016\/S0378-5173(99)00016-2","article-title":"Liposomes as carriers of the antiretroviral agent dideoxycytidine-5\u2032-triphosphate","volume":"180","author":"Oussoren","year":"1999","journal-title":"Int. J. Pharm."},{"issue":"10","key":"10.1016\/j.ejps.2015.04.011_b0460","doi-asserted-by":"crossref","first-page":"995","DOI":"10.2174\/0929867003374372","article-title":"Novel approaches for designing 5\u2032-O-ester prodrugs of 3\u2032-azido-2\u2032,3\u2032-dideoxythymidine (AZT)","volume":"7","author":"Parang","year":"2000","journal-title":"Curr. Med. Chem."},{"issue":"4","key":"10.1016\/j.ejps.2015.04.011_b0465","doi-asserted-by":"crossref","first-page":"488","DOI":"10.3390\/v4040488","article-title":"Nanotechnology and the treatment of HIV infection","volume":"4","author":"Parboosing","year":"2012","journal-title":"Viruses"},{"issue":"7","key":"10.1016\/j.ejps.2015.04.011_b0470","doi-asserted-by":"crossref","first-page":"666","DOI":"10.3109\/02652048.2012.680509","article-title":"Submicron-size biodegradable polymer-based didanosine particles for treating HIV at early stage: an in vitro study","volume":"29","author":"Pattnaik","year":"2012","journal-title":"J. Microencapsul."},{"key":"10.1016\/j.ejps.2015.04.011_b0475","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/j.jconrel.2014.03.048","article-title":"Carbosilane dendrimers as gene delivery agents for the treatment of HIV infection","volume":"184","author":"Peris\u00e9-Barrios","year":"2014","journal-title":"J. Control. Release"},{"issue":"3","key":"10.1016\/j.ejps.2015.04.011_b0480","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/S0166-3542(96)01011-X","article-title":"Red blood cells mediated delivery of 9-(2-phosphonylmethoxyethyl)adenine to primary macrophages: efficiency, metabolism and activity against human immunodeficiency virus or herpes simplex virus","volume":"33","author":"Perno","year":"1997","journal-title":"Antiviral Res."},{"issue":"2","key":"10.1016\/j.ejps.2015.04.011_b0485","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1310\/80JH-148K-NADQ-U927","article-title":"Reservoirs, sanctuaries, and residual disease: the hiding spots of HIV-1","volume":"4","author":"Pomerantz","year":"2003","journal-title":"HIV Clin. Trials"},{"issue":"2","key":"10.1016\/j.ejps.2015.04.011_b0490","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1177\/095632029400500205","article-title":"Decomposition pathways of the mono-(pivaloyl-oxymethyl) and bis(pivaloyl-oxymethyl) esters of azidothymidine 5\u2032-monophosphate in cell extract and in tissue-culture medium \u2013 an application of the online ISRP-cleaning HPLC technique","volume":"5","author":"Pompon","year":"1994","journal-title":"Antivir. Chem. Chemother."},{"issue":"3","key":"10.1016\/j.ejps.2015.04.011_b0495","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1111\/j.1468-1293.2005.00287.x","article-title":"Better maintained adherence on switching from twice-daily to once-daily therapy for HIV: a 24-week randomized trial of treatment simplification using stavudine prolonged-release capsules","volume":"6","author":"Portsmouth","year":"2005","journal-title":"HIV Med."},{"issue":"1","key":"10.1016\/j.ejps.2015.04.011_b0500","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0166-3542(96)01017-0","article-title":"Inhibition of human immunodeficiency virus type-1 replication in macrophages and H9 cells by free or liposome-encapsulated L-689,502, an inhibitor of the viral protease","volume":"34","author":"Pretzer","year":"1997","journal-title":"Antiviral Res."},{"issue":"1-2","key":"10.1016\/j.ejps.2015.04.011_b0505","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1016\/j.ijpharm.2012.04.054","article-title":"Investigation on the stability of saquinavir loaded liposomes: implication on stealth, release characteristics and cytotoxicity","volume":"431","author":"Ramana","year":"2012","journal-title":"Int. J. Pharm."},{"issue":"3\u20134","key":"10.1016\/j.ejps.2015.04.011_b0510","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1166\/jbn.2006.036","article-title":"Trans-activating transcriptional activator (TAT) peptide-mediated brain drug delivery","volume":"2","author":"Rao","year":"2006","journal-title":"J. Biomed. Nanotechnol."},{"issue":"8","key":"10.1016\/j.ejps.2015.04.011_b0515","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1517\/17425240903081705","article-title":"Targeting anti-HIV drugs to the CNS","volume":"6","author":"Rao","year":"2009","journal-title":"Expert Opin. Drug Deliv."},{"issue":"6","key":"10.1016\/j.ejps.2015.04.011_b0520","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1093\/jac\/47.6.819","article-title":"Erythrocyte-mediated delivery of a new homodinucleotide active against human immunodeficiency virus and herpes simplex virus","volume":"47","author":"Rossi","year":"2001","journal-title":"J. Antimicrob. Chemother."},{"issue":"10","key":"10.1016\/j.ejps.2015.04.011_b0525","doi-asserted-by":"crossref","first-page":"1577","DOI":"10.1093\/infdis\/jis395","article-title":"Pharmacodynamic and antiretroviral activities of combination nanoformulated antiretrovirals in HIV-1-infected human peripheral blood lymphocyte-reconstituted mice","volume":"206","author":"Roy","year":"2012","journal-title":"J. Infect. Dis."},{"issue":"4","key":"10.1016\/j.ejps.2015.04.011_b0530","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1080\/13550280903062813","article-title":"AZT 5\u2032-triphosphate nanoformulation suppresses human immunodeficiency virus type 1 replication in peripheral blood mononuclear cells","volume":"15","author":"Saiyed","year":"2009","journal-title":"J. Neurovirol."},{"key":"10.1016\/j.ejps.2015.04.011_b0535","first-page":"157","article-title":"Magnetic nanoformulation of azidothymidine 5\u2032-triphosphate for targeted delivery across the blood-brain barrier","volume":"5","author":"Saiyed","year":"2010","journal-title":"Int. J. Nanomed."},{"issue":"8","key":"10.1016\/j.ejps.2015.04.011_b0540","doi-asserted-by":"crossref","first-page":"1154","DOI":"10.3109\/03639045.2012.669129","article-title":"New sustained release of Zidovudine Matrix tablets \u2013 cytotoxicity toward Caco-2 cells","volume":"39","author":"Santos","year":"2013","journal-title":"Drug Dev. Ind. Pharm."},{"issue":"4","key":"10.1016\/j.ejps.2015.04.011_b0545","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1023\/A:1015852732512","article-title":"Phagocytosis of nanoparticles by human-immunodeficiency-virus (HIV)-infected macrophages \u2013 a possibility for antiviral drug targeting","volume":"9","author":"Schafer","year":"1992","journal-title":"Pharm. Res."},{"issue":"1","key":"10.1016\/j.ejps.2015.04.011_b0550","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/j.jconrel.2011.09.091","article-title":"Efficient CRM197-mediated drug targeting to monocytes","volume":"158","author":"Schenk","year":"2012","journal-title":"J. Control. Release"},{"issue":"2","key":"10.1016\/j.ejps.2015.04.011_b0555","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/j.antiviral.2008.09.006","article-title":"Effect of macrophage depletion on viral DNA rebound following antiretroviral therapy in a murine model of AIDS (MAIDS)","volume":"81","author":"Serafini","year":"2009","journal-title":"Antiviral Res."},{"key":"10.1016\/j.ejps.2015.04.011_b0560","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1016\/j.colsurfb.2012.06.038","article-title":"Poly(epsilon-caprolactone), Eudragit (R) RS 100 and poly(epsilon-caprolactone)\/Eudragit (R) RS 100 blend submicron particles for the sustained release of the antiretroviral efavirenz","volume":"102","author":"Seremeta","year":"2013","journal-title":"Colloid Surf. B-Biointerfaces"},{"issue":"2","key":"10.1016\/j.ejps.2015.04.011_b0565","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1177\/095632029300400203","article-title":"Synthesis and anti-HIV activity of prodrugs of azidothymidine","volume":"4","author":"Sharma","year":"1993","journal-title":"Antivir. Chem. Chemother."},{"issue":"2","key":"10.1016\/j.ejps.2015.04.011_b0570","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1016\/j.ijpharm.2011.09.041","article-title":"Surface modified nevirapine nanosuspensions for viral reservoir targeting: in vitro and in vivo evaluation","volume":"421","author":"Shegokar","year":"2011","journal-title":"Int. J. Pharm."},{"issue":"1-2","key":"10.1016\/j.ejps.2015.04.011_b0575","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1016\/j.ijpharm.2011.05.005","article-title":"A new nanomedicine based on didanosine glycerolipidic prodrug enhances the long term accumulation of drug in a HIV sanctuary","volume":"414","author":"Skanji","year":"2011","journal-title":"Int. J. Pharm."},{"issue":"8","key":"10.1016\/j.ejps.2015.04.011_b0580","doi-asserted-by":"crossref","first-page":"1750","DOI":"10.1007\/s11095-006-9026-1","article-title":"Feasibility of weekly HIV drug delivery to enhance drug localization in lymphoid tissues based on pharmacokinetic models of lipid-associated indinavir","volume":"23","author":"Snedecor","year":"2006","journal-title":"Pharm. Res."},{"issue":"6","key":"10.1016\/j.ejps.2015.04.011_b0585","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1097\/COH.0000000000000002","article-title":"Long-acting injectable antiretrovirals for HIV treatment and prevention","volume":"8","author":"Spreen","year":"2013","journal-title":"Curr. Opin. HIV AIDS"},{"issue":"9","key":"10.1016\/j.ejps.2015.04.011_b0590","doi-asserted-by":"crossref","first-page":"1425","DOI":"10.1016\/S0006-2952(99)00224-5","article-title":"Homing of negatively charged albumins to the lymphatic system \u2013 general implications for drug targeting to peripheral tissues and viral reservoirs","volume":"58","author":"Swart","year":"1999","journal-title":"Biochem. Pharmacol."},{"issue":"5","key":"10.1016\/j.ejps.2015.04.011_b0595","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1093\/infdis\/jir370","article-title":"The critical need for alternative antiretroviral formulations, and obstacles to their development","volume":"204","author":"Swindells","year":"2011","journal-title":"J. Infect. Dis."},{"issue":"5","key":"10.1016\/j.ejps.2015.04.011_b0600","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1089\/aid.1990.6.691","article-title":"Inhibition of HIV-1 in monocyte macrophage cultures by 2\u2032,3\u2032-dideoxycytidine-5\u2032-triphosphate, free and in liposomes","volume":"6","author":"Szebeni","year":"1990","journal-title":"Aids Res. Hum. Retrovir."},{"issue":"1","key":"10.1016\/j.ejps.2015.04.011_b0605","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1007\/s10571-004-1383-x","article-title":"Mechanisms of the blood-brain barrier disruption in HIV-1 infection","volume":"25","author":"Toborek","year":"2005","journal-title":"Cell. Mol. Neurobiol."},{"issue":"11","key":"10.1016\/j.ejps.2015.04.011_b0610","doi-asserted-by":"crossref","DOI":"10.1007\/s11051-013-2040-4","article-title":"Nanoencapsulation of water-soluble drug, lamivudine, using a double emulsion spray-drying technique for improving HIV treatment","volume":"15","author":"Tshweu","year":"2013","journal-title":"J. Nanopart. Res."},{"issue":"17","key":"10.1016\/j.ejps.2015.04.011_b0615","doi-asserted-by":"crossref","first-page":"3418","DOI":"10.1021\/jm950777g","article-title":"Synthesis and antiretroviral evaluation of new alkoxy and aryloxy phosphate derivatives of 3\u2032-azido-3\u2032-deoxythymidine","volume":"39","author":"Tsotinis","year":"1996","journal-title":"J. Med. Chem."},{"issue":"4","key":"10.1016\/j.ejps.2015.04.011_b0620","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1002\/jps.2600830407","article-title":"Adamantane as a brain-directed drug carrier for poorly absorbed drug. 2. Azt derivatives conjugated with the 1-adamantane moiety","volume":"83","author":"Tsuzuki","year":"1994","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.ejps.2015.04.011_b0625","unstructured":"US Department of Health and Human Services, 2013. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. <http:\/\/aidsinfo.nih.gov\/ContentFiles\/AdultandAdolescentGL.pdf>."},{"issue":"2","key":"10.1016\/j.ejps.2015.04.011_b0630","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1177\/135965350701200216","article-title":"A Phase I\/IIa study with succinylated human serum albumin (Suc-HSA), a candidate HIV-1 fusion inhibitor","volume":"12","author":"Vermeulen","year":"2007","journal-title":"Antiviral Therapy"},{"issue":"6","key":"10.1016\/j.ejps.2015.04.011_b0635","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1021\/mp0500364","article-title":"Cross-linked polymeric nanogel formulations of 5\u2032-triphosphates of nucleoside analogues: role of the cellular membrane in drug release","volume":"2","author":"Vinogradov","year":"2005","journal-title":"Mol. Pharm."},{"issue":"3","key":"10.1016\/j.ejps.2015.04.011_b0640","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1211\/jpp.58.3.0005","article-title":"Development and characterization of emulsomes for sustained and targeted delivery of an antiviral agent to liver","volume":"58","author":"Vyas","year":"2006","journal-title":"J. Pharm. Pharmacol."},{"issue":"11","key":"10.1016\/j.ejps.2015.04.011_b0645","doi-asserted-by":"crossref","first-page":"2110","DOI":"10.1007\/s11095-007-9402-5","article-title":"Peritoneal macrophage uptake, pharmacokinetics and biodistribution of macrophage-targeted PEG-fMLF (N-formyl-methionyl-leucyl-phenylalanine) nanocarriers for improving HIV drug delivery","volume":"24","author":"Wan","year":"2007","journal-title":"Pharm. Res."},{"issue":"3","key":"10.1016\/j.ejps.2015.04.011_b0650","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1208\/s12249-008-9122-0","article-title":"A novel anti-HIV dextrin-zidovudine conjugate improving the pharmacokinetics of zidovudine in rats","volume":"9","author":"Wannachaiyasit","year":"2008","journal-title":"AAPS Pharmscitech."},{"issue":"4-5","key":"10.1016\/j.ejps.2015.04.011_b0655","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1016\/j.addr.2009.11.020","article-title":"Nanotechnology applications for improved delivery of antiretroviral drugs to the brain","volume":"62","author":"Wong","year":"2010","journal-title":"Adv. Drug Deliv. Rev."},{"issue":"1","key":"10.1016\/j.ejps.2015.04.011_b0660","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/j.bmc.2009.11.013","article-title":"Synthesis, nanosizing and in vitro drug release of a novel anti-HIV polymeric prodrug: chitosan-O-isopropyl-5\u2032-O-d4T monophosphate conjugate","volume":"18","author":"Yang","year":"2010","journal-title":"Bioorg. Med. Chem."},{"issue":"1","key":"10.1016\/j.ejps.2015.04.011_b0665","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1016\/j.jconrel.2009.03.002","article-title":"Albumin nanoparticles targeted with Apo E enter the CNS by transcytosis and are delivered to neurones","volume":"137","author":"Zensi","year":"2009","journal-title":"J. Control. Release"}],"container-title":["European Journal of Pharmaceutical Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0928098715001542?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0928098715001542?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2022,5,7]],"date-time":"2022-05-07T01:23:37Z","timestamp":1651886617000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0928098715001542"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,7]]},"references-count":133,"alternative-id":["S0928098715001542"],"URL":"https:\/\/doi.org\/10.1016\/j.ejps.2015.04.011","relation":{},"ISSN":["0928-0987"],"issn-type":[{"value":"0928-0987","type":"print"}],"subject":[],"published":{"date-parts":[[2015,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Improving bioavailability and biodistribution of anti-HIV chemotherapy","name":"articletitle","label":"Article Title"},{"value":"European Journal of Pharmaceutical Sciences","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejps.2015.04.011","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2015 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}